QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NYSE:CTV

Innovid (CTV) Stock Forecast, Price & News

$1.17
-0.07 (-5.65%)
(As of 09/26/2023 ET)
Compare
Today's Range
$1.14
$1.24
50-Day Range
$1.05
$1.38
52-Week Range
$0.75
$3.74
Volume
251,992 shs
Average Volume
440,557 shs
Market Capitalization
$162.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.35

Innovid MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
186.3% Upside
$3.35 Price Target
Short Interest
Healthy
1.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$181,300 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.22) to ($0.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Computer And Technology Sector

290th out of 582 stocks

Prepackaged Software Industry

85th out of 203 stocks


CTV stock logo

About Innovid (NYSE:CTV) Stock

Innovid Corp. operates an independent software platform that provides ad serving, measurement, and creative services. The company offers advertising services for the creation, delivery, and measurement of TV ads across connected TV, mobile TV, and desktop TV environments to advertisers, publishers, and media agencies. It also provides creative management; advertising measurement; identity resolution; and publisher solutions. The company serves consumer packaged goods, pharmaceutical and healthcare, financial services, and automotive and technology industries; third party agencies; and publishers in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Innovid Corp. was incorporated in 2007 and is headquartered in New York, New York.

CTV Price History

CTV Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
JMP Securities Sticks to Its Buy Rating for Innovid (CTV)
Innovid Slips To Loss In Q2, Misses Estimates; Lifts FY23 Outlook
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Innovid Reports Q2 2023 Financial Results
Innovid's David Helmreich Acquires 17% More Stock
See More Headlines
Receive CTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovid and its competitors with MarketBeat's FREE daily newsletter.

CTV Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
531
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.35
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.40
Forecasted Upside/Downside
+179.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-18,410,000.00
Pretax Margin
-27.33%

Debt

Sales & Book Value

Annual Sales
$133.20 million
Book Value
$1.54 per share

Miscellaneous

Free Float
125,512,000
Market Cap
$167.16 million
Optionable
Not Optionable
Beta
2.94
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Prof. Zvika Netter (Age 50)
    Co-Founder, CEO & Chair of the Board
    Comp: $749.87k
  • Mr. Tal Chalozin (Age 41)
    Co-Founder
    Comp: $400.09k
  • Ms. Tanya Andreev-Kaspin (Age 45)
    Chief Financial Officer
    Comp: $575.13k
  • Mr. Ken Markus (Age 48)
    Chief Operating Officer
  • Mr. Yuval Pemper (Age 52)
    Chief Technology Officer
  • John T. Williams
    Head of Investor Relations
  • Stephen Cook
    Gen. Counsel
  • Mr. Tim Braz
    EVP of Global Sales
  • Ms. Liel Golan
    Sr. VP of HR
  • Mr. Arik Shahar
    Sr. VP of Identity & Measurement













CTV Stock - Frequently Asked Questions

Should I buy or sell Innovid stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovid in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTV shares.
View CTV analyst ratings
or view top-rated stocks.

What is Innovid's stock price forecast for 2023?

3 analysts have issued twelve-month price targets for Innovid's stock. Their CTV share price forecasts range from $1.40 to $5.00. On average, they predict the company's stock price to reach $3.35 in the next year. This suggests a possible upside of 179.2% from the stock's current price.
View analysts price targets for CTV
or view top-rated stocks among Wall Street analysts.

How have CTV shares performed in 2023?

Innovid's stock was trading at $1.71 at the beginning of the year. Since then, CTV shares have decreased by 29.8% and is now trading at $1.20.
View the best growth stocks for 2023 here
.

Are investors shorting Innovid?

Innovid saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,530,000 shares, a decline of 20.3% from the August 15th total of 1,920,000 shares. Based on an average daily trading volume, of 529,800 shares, the days-to-cover ratio is presently 2.9 days. Approximately 1.8% of the company's stock are sold short.
View Innovid's Short Interest
.

When is Innovid's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 10th 2023.
View our CTV earnings forecast
.

How were Innovid's earnings last quarter?

Innovid Corp. (NYSE:CTV) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The firm earned $34.55 million during the quarter, compared to the consensus estimate of $32.90 million. Innovid had a negative trailing twelve-month return on equity of 14.09% and a negative net margin of 32.12%.

What guidance has Innovid issued on next quarter's earnings?

Innovid updated its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $33.00 million-$35.00 million, compared to the consensus revenue estimate of $32.80 million.

What is Innovid's stock symbol?

Innovid trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTV."

Who are Innovid's major shareholders?

Innovid's stock is owned by many different retail and institutional investors. Top institutional shareholders include Whetstone Capital Advisors LLC (2.60%), Royce & Associates LP (2.03%), Goldman Sachs Group Inc. (1.86%), Renaissance Technologies LLC (0.61%), Geode Capital Management LLC (0.53%) and State Street Corp (0.19%). Insiders that own company stock include David Helmreich, Gilad Shany, Tal Chalozin, Tanya Andreev-Kaspin and Zvika Netter.
View institutional ownership trends
.

How do I buy shares of Innovid?

Shares of CTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innovid's stock price today?

One share of CTV stock can currently be purchased for approximately $1.20.

How much money does Innovid make?

Innovid (NYSE:CTV) has a market capitalization of $167.16 million and generates $133.20 million in revenue each year. The company earns $-18,410,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does Innovid have?

The company employs 531 workers across the globe.

How can I contact Innovid?

Innovid's mailing address is 89 MEDINAT HAYEHUDIM STREET, HERZLIYA L3, 4676672. The official website for the company is www.ion-am.com. The company can be reached via phone at 212-966-7555 or via email at investors@innovid.com.

This page (NYSE:CTV) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -